HIV-Associated Malignancies

- Cancer remains a major problem in the management of HIV infection in all areas of the world.
- Non AIDS-defining cancers include Hodgkin's disease, anal, lung, hepatocellular, and head and neck cancers.
- The incidence of these cancers and other cancers are increasing despite the benefits of highly active antiretroviral therapy.
- For people with HIV disease, the list of AIDS-defining cancers include Kaposi’s sarcoma, cervical cancer, aggressive non-Hodgkin’s lymphomas and primary central nervous system lymphoma.

Contact us:
Telephone: (301) 251-1161
Fax: (240) 238-2842
E-mail: amcpm@emmes.com
http://www.AIDSCancer.org

AMC INSTITUTIONS

United States Sites:
1. Abramson Cancer Center, Pennsylvania Hosp. ☏ (215) 829-6311
2. Albert Einstein Cancer Center/Montefiore ☏ (718) 920-5636
3. Baylor College of Medicine ☏ (713) 873-4054
4. Beth Israel Deaconess Medical Center ☏ (617) 667-2731
5. Boston Medical Center ☏ (617) 414-5175
6. Fred Hutchinson Cancer Research Center ☏ (206) 667-5524
7. Harborview Medical Center ☏ (206) 667-5524
8. Memorial Sloan-Kettering Cancer Center ☏ (212) 639-7423
9. University of California, Los Angeles ☏ (310) 557-3729
10. University of California, San Diego ☏ (858) 822-5363
11. University of California, San Francisco ☏ (415) 353-2661
12. University of Miami ☏ (305) 243-6611
13. Virginia Mason Medical Center ☏ (206) 342-6854
14. John H. Stroger Jr. Hospital of Cook County ☏ (312) 864-7277
15. Johns Hopkins University ☏ (410) 955-5617
16. Laser Surgery Care ☏ (212) 242-6500
17. Louisiana State Univ. Health Sciences Center ☏ (504) 568-3421
18. Ohio State University ☏ (614) 293-5066
19. University of California, Davis Medical Center ☏ (916) 914-6319
20. University of North Carolina at Chapel Hill ☏ (919) 966-4432
21. University of Pittsburgh ☏ (412) 647-8125
22. University of Puerto Rico ☏ (787) 772-8300
23. Washington University ☏ (314) 362-8836
24. Wake Forest University Health Sciences ☏ (336) 716-8918
25. Weill Medical College of Cornell University ☏ (212) 746-7163

International Sites:
Kenya
1. Moi University, School of Medicine ☏ +254-722496933

Zimbabwe
2. University of Zimbabwe ☏ +263-4-791631

Uganda
3. Uganda Cancer Institute ☏ +256-341-540410

South Africa
4. University of the Witwatersrand ☏ +27-11-276-8860

Revised (Version 2.0; 05/22/2014)
The AMC mission is to investigate new treatment and prevention interventions for malignancies in people living with HIV and to study the pathobiology of these tumors in the context of clinical trials.

The AMC is a National Cancer Institute consortium founded in 1995 to support innovative trials for cancers in people with HIV/AIDS.

The AMC is composed of the following working groups:

- **Kaposi’s Sarcoma**
- **Lymphoma**
- **Translational Sciences**
- **Human Papillomavirus (HPV) and Anal Cancer**
- **Non AIDS-defining Cancer**
- **Behavioral Research**

And, the following two committees:

- **International Activities**
- **Outreach, Education, Recruitment and Retention**

The AMC assists medical care providers and their HIV infected patients with HIV infection by focusing on cancer prevention and treatment studies.

~*~

Lymphoma Clinical Trials

- **AMC-053**: Safety and Efficacy Trial of The Anti-Viral and Anti-Tumor Activity of Velcade Combined with (R) ICE in Subjects with Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
- **AMC-075**: A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-adapted Chemotherapy with Rituximab in HIV-related B-cell Non-Hodgkin's Lymphoma
- **AMC-080**: Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals
- **AMC-085**: A Phase 1/2 Study Examining AVD and Brentuximab Veddootin in Patients with HIV and Advanced Stage Hodgkin’s Lymphoma

Human Papillomavirus (HPV) and Anal Cancer Clinical Trials

- **AMC-A01**: ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study
- **AMC-058**: A Comparison Protocol to Evaluate Anogenital Human Papillomavirus (HPV) Infection and Anogenital Squamous Intraepithelial Lesions (ASIL) in Patients Participating in AMC Clinical Trials
- **AMC-072**: Protective Effect of Quadrivalent Vaccine in Young HIV-positive Males who have Sex with Males
- **AMC-076**: A Randomized Clinical Trial of Infrared Coagulation IRC Ablation versus Expectant Management of Intra-anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Subjects

Kaposi Sarcoma Clinical Trials

- **AMC-084**: Screening HIV-Infected Women for Anal Cancer Precursors Screening HIV-Infected Women for Anal Cancer Precursors
- **AMC-088**: A Randomized, Phase III Study of Intra-anal Imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women

Non-AIDS Defining Cancer Clinical Trials

- **AMC-078**: A Phase 1 Study of Paclitaxel and Carboplatin in Solid Tumors (with focus on Upper Aerodigestive Cancers) in Persons with HIV Infection
- **AMC-087**: Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons with HIV Infection
- **AMC-089**: A Phase II Study of Gamma Secretase Inhibitor PF-03084014 in Patients with AIDS-Associated Kaposi Sarcoma

International Activities Clinical Trials

- **AMC-068**: Phase II Study of Oral Chemotherapy for AIDS-Related Non-Hodgkin’s Lymphoma (AR-NHL) in Africa
- **AMC-081**: Feasibility Study of Safety, Toxicity, and Compliance of Concomitant Chemoradiotherapy for HIV-Associated Locally-Advanced Cervical Cancer